These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 22899341)
1. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. Grosse-Gehling P; Fargeas CA; Dittfeld C; Garbe Y; Alison MR; Corbeil D; Kunz-Schughart LA J Pathol; 2013 Feb; 229(3):355-78. PubMed ID: 22899341 [TBL] [Abstract][Full Text] [Related]
2. Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name? Neuzil J; Stantic M; Zobalova R; Chladova J; Wang X; Prochazka L; Dong L; Andera L; Ralph SJ Biochem Biophys Res Commun; 2007 Apr; 355(4):855-9. PubMed ID: 17307142 [TBL] [Abstract][Full Text] [Related]
3. Targeting CD133 antigen in cancer. Ferrandina G; Petrillo M; Bonanno G; Scambia G Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986 [TBL] [Abstract][Full Text] [Related]
4. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. Horst D; Scheel SK; Liebmann S; Neumann J; Maatz S; Kirchner T; Jung A J Pathol; 2009 Dec; 219(4):427-34. PubMed ID: 19621338 [TBL] [Abstract][Full Text] [Related]
5. Biology and clinical implications of CD133(+) liver cancer stem cells. Ma S Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864 [TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data. Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019 [TBL] [Abstract][Full Text] [Related]
7. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Park EK; Lee JC; Park JW; Bang SY; Yi SA; Kim BK; Park JH; Kwon SH; You JS; Nam SW; Cho EJ; Han JW Cell Death Dis; 2015 Nov; 6(11):e1964. PubMed ID: 26539911 [TBL] [Abstract][Full Text] [Related]
8. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. Botchkina IL; Rowehl RA; Rivadeneira DE; Karpeh MS; Crawford H; Dufour A; Ju J; Wang Y; Leyfman Y; Botchkina GI Cancer Genomics Proteomics; 2009; 6(1):19-29. PubMed ID: 19451087 [TBL] [Abstract][Full Text] [Related]
9. High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals. Cortes-Dericks L; Galetta D; Spaggiari L; Schmid RA; Karoubi G Eur J Cardiothorac Surg; 2012 Jun; 41(6):e173-81. PubMed ID: 22529186 [TBL] [Abstract][Full Text] [Related]
10. Expression of CD133 in synovial sarcoma. Terry J; Nielsen T Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):159-65. PubMed ID: 19752721 [TBL] [Abstract][Full Text] [Related]
11. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells. Barrantes-Freer A; Renovanz M; Eich M; Braukmann A; Sprang B; Spirin P; Pardo LA; Giese A; Kim EL PLoS One; 2015; 10(6):e0130519. PubMed ID: 26086074 [TBL] [Abstract][Full Text] [Related]
12. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme. Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652 [TBL] [Abstract][Full Text] [Related]
13. CD133: holy of grail of neuro-oncology or promiscuous red-herring? Donovan LK; Pilkington GJ Cell Prolif; 2012 Dec; 45(6):527-37. PubMed ID: 23106300 [TBL] [Abstract][Full Text] [Related]
14. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression. Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848 [TBL] [Abstract][Full Text] [Related]
15. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143 [TBL] [Abstract][Full Text] [Related]
16. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases. Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240 [TBL] [Abstract][Full Text] [Related]
17. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. Bidlingmaier S; Zhu X; Liu B J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813 [TBL] [Abstract][Full Text] [Related]
18. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment. Lönnroth C; Andersson M; Nordgren S; Lundholm K Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364 [TBL] [Abstract][Full Text] [Related]
19. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer. Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798 [TBL] [Abstract][Full Text] [Related]
20. The potential role of CD133 in immune surveillance and apoptosis: a mitochondrial connection? Zobalova R; Prokopova K; Stantic M; Stapelberg M; Dong LF; Ralph SJ; Akporiaye E; Neuzil J Antioxid Redox Signal; 2011 Dec; 15(12):2989-3002. PubMed ID: 21504364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]